A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.


Updates from The Motley Fool

Latest updates on Valeant Pharmaceuticals from Fool.com.  The Fool has written over 400 articles on Valeant Pharmaceuticals.
Is Valeant Turning Things Around?

With a new CEO, Valeant seems to be trying to recover from their 2015 debacle, but will the compa...



Stock Performance

View Interactive VRX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Valeant Pharmaceuticals.
Current Price: $19.71
Prev Close: $19.68
Open: $19.70
Bid: $19.69
Ask: $19.70
Day's Range: $19.20 - $20.39
52wk Range: $8.31 - $22.81
Volume: 23,768,443
Avg Vol 23,582,566
Market Cap: $7B
P/E (ttm): 5.03
EPS (ttm): $3.91
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Valeant Pharmaceuticals.
CAPS Rating 2 out of 5
 
498 Outperform
80 Underperform
CAPS All Stars
 
89 Outperform
28 Underperform

How do you think Valeant Pharmaceuticals will perform against the market?



You pick for Valeant Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Joseph C. Papa, CEO

70% Approve

Based on 29 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Valeant Pharmaceuticals.

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

  • Exchange: NYSE
  • Sector: Healthcare
  • Industry: Drug Makers